TTK Healthcare Limited (TTKHLTCARE) — Annual Report(3 announcements)

TTK Healthcare Limited announced its 68th AGM on July 24, 2026, via video conference, alongside the FY 2025-26 Annual Report. Key highlights include reappointment of Executive Chairman T T Raghunathan for 5 years, dividend declaration, director reappointments, and resolutions on remuneration. The filing details AGM procedures, remote e-voting via CDSL, dividend eligibility (record date July 17), TDS rules, and shareholder documentation requirements. Strategic focus areas include growth in medical devices, animal welfare, and pleasure products, with opportunities in Ayushman Bharat and export markets. Risks include input cost volatility and geopolitical instability. Financials show revenue of Rs. 85,728.11 lakhs, PAT of Rs. 6,568.05 lakhs, and margin pressures. Governance disclosures cover board composition, CSR spending of Rs. 165 lakhs, and compliance with SEBI LODR. No material fraud or regulatory actions were reported.

TTK Healthcare Limited's FY2025-26 Annual Report details its Business Responsibility and Sustainability Report (BRSR) filed on June 27, 2026, covering standalone disclosures for the year ending March 31, 2026. The report outlines business operations, sustainability initiatives, risk management, and compliance across 9 NGRBC principles. Key highlights include standalone financials, employee welfare programs, environmental targets, and stakeholder engagement. No material changes from prior periods were noted, with no forward guidance provided. The company emphasizes sustainable product development, energy efficiency, and community health initiatives, while maintaining zero non-compliance with environmental regulations. Governance is overseen by the Board and CEO, with no independent assurance provided for BRSR disclosures.

TTK Healthcare Limited announced its 68th AGM scheduled for July 24, 2026 via video conferencing, with resolutions including reappointment of Executive Chairman T T Raghunathan for 5 years, dividend declaration of Rs.1,413.03 per share at 100% rate, and approval of cost auditor remuneration of Rs.6 lakhs plus taxes. The filing details e-voting arrangements via CDSL, shareholder communication protocols, and compliance requirements for remote participation. Key financial highlights include FY 2025-26 revenue of Rs.857.28 crores, profit after tax of Rs.6,568.05 lakhs, and employee strength of 1,478. Strategic focus areas include expansion in medical devices and pet care segments, while risks include input cost volatility and geopolitical instability. The company also disclosed CSR expenditure of Rs.165 lakhs, with no unspent amount transferred, and outlined governance practices including board committee structures and stakeholder engagement frameworks.